Evidence map›Paper›PMID 40199835›Full record

ArticleInternational journal of behavioral medicine2026

Facilitators and Barriers to Uptake of Genetic and Cascade Testing in Familial Hypercholesterolemia: a Systematic Review.

Chaitanyasre Lenin, Phoebe X H Lim, Ashna Nastar, Tavintharan Subramaniam, Sharon Pek, Magdalena Daccord, Elsie Evans, Emma Print, Frederick H F Chan, Konstadina Griva

Abstract read
In one paragraph

Article in International journal of behavioral medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Measuring disease likelihood in genomic ascertainment.American journal of human genetics · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chaitanyasre LeninLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Phoebe X H LimLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Ashna NastarDivision of Endocrinology, Alexandra Hospital, Singapore, Singapore.
Tavintharan SubramaniamDiabetes Centre Admiralty Medical Centre, Division of Endocrinology, Department of Medicine, Khoo Teck Puat Hospital, Singapore, Singapore.
Sharon PekClinical Research Unit, Khoo Teck Puat Hospital, Singapore, Singapore.
Magdalena DaccordFH Europe Foundation, Amsterdam, The Netherlands.
Elsie EvansFH Europe Foundation, Amsterdam, The Netherlands.
Emma PrintFH Europe Foundation, Amsterdam, The Netherlands.
Frederick H F ChanLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Konstadina GrivaLee Kong Chian School of Medicine, Nanyang Technological University, Level 18, Clinical Sciences Building, 11 Mandalay Road, Singapore, 308232, Singapore. konstadina.griva@ntu.edu.sg.ORCID http://orcid.org/0000-0001-8173-5663

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFamilial hypercholesterolemia (FH) is an underdiagnosed autosomal dominant genetic disorder that confers high but preventable risk for premature adverse cardiovascular events. Timely diagnosis is limited by low uptake of genetic testing (GT) and cascade testing (CT). This systematic review identifies barriers and facilitators for uptake of GT and CT in FH.

methodFollowing PRISMA guidelines, seven databases were searched for studies on GT/CT in FH. Data reporting standards for qualitative studies were evaluated with COREQ and thematic synthesis was conducted. Of the 387 studies identified, 15 were included (qualitative N = 9, quantitative N = 6). These involved 272,954 respondents (qualitative n = 243, quantitative n = 272,711). COREQ scores ranged from 11 to 21 out of 32.

resultsSynthesis of qualitative data indicated family history of illness, being well informed, and value of GT as key facilitators of GT. Financial concerns, suboptimal clinical care, and no/low value of GT were identified as barriers. Facilitators of CT included responsibility to family, healthcare providers' support for CT, and gains of CT, while barriers included disconnect from family, emotional costs, and no value knowing FH status. Quantitative studies reflect emotional distress avoidance, limited opportunity for family disclosure to invite, lack of knowledge, low communication efficacy, and difficulties accessing testing services as predictors impacting CT.

conclusionBeyond knowledge, perceptions about testing-especially perceived value of testing-emerged to be significantly affecting decisions for GT/CT. Disconnect from family is a maior predictor in CT, reducing the likelihood of probands extending an invitation to their family in support of CT. Future interventions should address barriers and facilitators at interpersonal, clinical and systemic levels to improve FH GT/CT uptake. Additionally, further research in diverse cultural contexts is required to bridge gaps in GT/CT services. Interventions should especially prioritize risk perception education and the development of health communication tools to supplement strong clinical guidance, driving a more patient-centered approach in decisions relating to GT/CT.

Indexed as

BarriersCardiovascular diseaseCascade testingFacilitatorsFHGenetic testingPrecision medicinePublic health

Identifiers

PMID40199835
PMCPMC12935743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.